comparative effectiveness

Prostate Cancer Treatment Associated With More Adverse Events

06/10/2016

JCP Editors

Patients with metastatic castrate resistant prostate cancer treated with enzalutamide (ENZ) may be more likely to experience central nervous system adverse events and fatigue than those who receive a combination of...

...

06/10/2016

Journal of Clinical Pathways

06/09/2016

JCP Editors

Health-related quality of life (HRQoL) and its impact on disease progression should be a critical consideration when selecting treatment for patients with soft-tissue sarcoma (STS),...

...

06/09/2016

Journal of Clinical Pathways

Department

Pembrolizumab Leads to Improved Survival in Patients With Melanoma

06/06/2016

JCP Editors

Patients with advanced melanoma treated with a Programmed cell death protein-1 (PD-1) immune checkpoint inhibitor have longer survival than historically treated patients, according to results from a phase 1 clinical...

...

06/06/2016

Journal of Clinical Pathways

Drug Combination Reduces Adverse Events and Need for Dose Reductions

06/02/2016

JCP Editors

The addition of plinabulin to non-small cell lung cancer (NSCLC) treatment with docetaxel may reduce the frequency of adverse events and help prevent dose reductions due to toxicity, according to an abstract at the...

The...

06/02/2016

Journal of Clinical Pathways

Research in Review

Review of EGFR Mutation-Positive NSCLC Drugs Identifies Optimal Treatments

06/02/2016

JCP Editors

A review of treatments for non-small cell lung cancer (NSCLC) that is epidermal growth factor receptor mutation positive (EGFR M+) has identified which therapies are the most effective at managing disease symptoms...

A...

06/02/2016

Journal of Clinical Pathways

Research in Review

FDA Approval Process Flawed for Cancer Drugs

05/30/2016

JCP Editors

A study published in Mayo Clinic Proceedings has called into question how the Food and Drug Administration (FDA) uses surrogate endpoints in approvals for certain cancer medications. Surrogate endpoints are measures...

A...

05/30/2016

Journal of Clinical Pathways

Research in Review

Post-Progression Nivolumab Treatment Effective for Patients With RCC

05/16/2016

JCP Editors

Patients with renal cell carcinoma may continue to benefit from treatment with nivolumab even after the disease has progressed, according a study published JAMA Oncology. Still a relatively new line of treatments,...

...

05/16/2016

Journal of Clinical Pathways

Research in Review

Evolution of Treatment Strategies for Renal Cancer

05/13/2016

JCP Editors

A look at 14 years of health care trends has revealed that the percentage of patients receiving treatment for metastatic renal cell carcinoma (mRCC) is growing as providers shift toward targeted therapeutic...

A look...

05/13/2016

Journal of Clinical Pathways

Research in Review

Chemoradiotherapy Does Not Improve Survival for Patients With Pancreatic Cancer

05/11/2016

JCP Editors

Adding radiation to chemotherapy regimens may not improve overall survival compared with chemotherapy alone in patients with locally advanced pancreatic cancer, according to results from a clinical trial. The trial,...

Adding...

05/11/2016

Journal of Clinical Pathways

Strict Adherence to Ibrutinib Therapy Improves PFS for Chronic Lymphocytic Leukemia

05/05/2016

JCP Editors

Ibrutinib may improve progression-free survival (PFS) for patients with chronic lymphocytic leukemia (CLL) if the full dose is taken on schedule, according to results extracted from clinical trial data and presented...

...

05/05/2016

Journal of Clinical Pathways